Gilead Sciences, Inc.
GILD
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment ofā¦ read more
Healthcare
Drug ManufacturersāGeneral
34 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$139.71
Price-0.42%
-$0.59
1Y
Price
Market Cap
$173.439b
Large
Price/Earnings 3y Avg5y Avg
17.1x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+29.4%
EBITDA Margin+27.6%
Net Profit Margin+39.4%
Free Cash Flow Margin+29.4%
EBITDA Margin+27.6%
Net Profit Margin+39.4%
Free Cash Flow MarginRevenue
$29.443b
+2.4%
1y CAGR+2.6%
3y CAGR+1.9%
5y CAGREarnings
$8.510b
+1672.9%
1y CAGR+534.9%
3y CAGR+394.6%
5y CAGREPS
$6.78
+1681.6%
1y CAGR+537.9%
3y CAGR+396.9%
5y CAGRBook Value
$22.618b
$59.023b
Assets$36.405b
Liabilities$24.592b
DebtDebt to Assets
41.7%
1.9x
Debt to EBITDAFree Cash Flow
$9.456b
-8.2%
1y CAGR+6.5%
3y CAGR-0.8%
5y CAGRNo items found.
Press Releases
Statements and updates from the company